3 Contract Manufacturing, Hydration Formulation and Life Science Service Stocks With a Strong Future Roadmap: Akums Drugs and Pharmaceuticals, FDC and Indegene
- October 14, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Akums Rs 769.30, P/E 42.26. FDC Rs 338.45, P/E 18.05. Indegene Rs 580.70, P/E 35.20. Closing prices of 13 Oct 2026.
Quick Answer
Contract manufacturing, hydration formulation and life science service stocks with the clearest long-term roadmaps today include Akums in contract development and manufacturing of pharmaceutical and nutraceutical products, FDC in oral rehydration products, ophthalmic and other branded formulations and Indegene in commercial, medical and regulatory services for life science companies. FY26 revenue growth was 7.6% at Akums, 3.9% at FDC and 21.6% at Indegene. P/E stands at 42.26 for Akums (industry 37.59), 18.05 for FDC (industry 37.59) and 35.20 for Indegene (industry 62.79). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Contract manufacturing, hydration formulation and life science service stocks give investors exposure to medicines and services that drug brands, doctors and patients rely on. Contract orders, prescription growth and client wins decide how much of that demand turns into profit.
This list covers three contract manufacturing, hydration formulation and life science service stocks: Akums Drugs and Pharmaceuticals for contract development and manufacturing of pharmaceutical and nutraceutical products, FDC for oral rehydration products, ophthalmic and other branded formulations and Indegene for commercial, medical and regulatory services for life science companies. Every figure comes from the latest reported financials and the 13 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Contract Manufacturing, Hydration Formulation and Life Science Service Stocks?
Contract manufacturing, hydration formulation and life science service stocks are shares of companies that manufacture for drug brands, sell formulations or serve drug makers. Results depend on contract orders, prescription growth and client wins, so growth and margins separate the stronger names.
Contract Manufacturing, Hydration Formulation and Life Science Service Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three contract manufacturing, hydration formulation and life science service stocks as of the 13 Oct 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| Akums Drugs and Pharmaceuticals | 769.30 | 12,370 | 42.26 | 37.59 | 7.70% | 0.05 |
| FDC | 338.45 | 5,281 | 18.05 | 37.59 | 11.32% | 0.01 |
| Indegene | 580.70 | 14,110 | 35.20 | 62.79 | 12.78% | 0.05 |
Among healthcare stocks, Akums trades at a premium to the industry P/E, while FDC and Indegene trade at a discount.
Why Do Contract Manufacturing, Hydration Formulation and Life Science Service Stocks Have a Strong Roadmap in India?
Contract manufacturing, hydration formulation and life science service stocks have a strong roadmap in India because outsourced drug making, steady branded demand and life science outsourcing keep lifting these healthcare firms. Three drivers stand out.
- Outsourced making: Brands hand manufacturing to specialist plants.
- Branded demand: Trusted brands keep repeat prescriptions flowing.
- Life science outsourcing: Drug makers buy commercial and medical support.
Akums Drugs and Pharmaceuticals: Contract Manufacturing Anchors the Roadmap
Akums’ roadmap rests on contract development and manufacturing of pharmaceutical and nutraceutical products, with outsourcing demand from drug companies supporting orders.
Revenue grew from Rs 3,694.52 crore in FY22 to Rs 4,487.74 crore in FY26, a 21.5% rise, and FY26 revenue was 7.6% higher than FY25. FY26 net profit was Rs 256.40 crore. In Q1 FY27, revenue grew 13.9% to Rs 1,197.01 crore, and net profit rose 56.1% to Rs 100.98 crore. Operating margin was 14.47% in FY26 and 17.58% in Q1 FY27 against 15.20% a year earlier.
Debt to equity is 0.05 and return on equity is 7.70%. FY26 operating cash flow was Rs 1,181.20 crore against capital expenditure of Rs 230.53 crore. Akums paid a dividend of Rs 3 per share for FY26, a yield of 0.37%. At a P/E of 42.26 against an industry P/E of 37.59, the stock trades above its industry multiple.
What to watch: Return on equity of 7.70% is modest.
FDC: Established Brands Drive the Pipeline
FDC’s roadmap rests on oral rehydration products such as Electral along with eye, ear and anti-infective formulations, with established brands supporting steady sales.
Revenue grew from Rs 1,604.01 crore in FY22 to Rs 2,284.45 crore in FY26, a 42.4% rise, and FY26 revenue was 3.9% higher than FY25. FY26 net profit rose 5.5% to Rs 281.42 crore. Over four years, net profit rose from Rs 216.16 crore in FY22 to Rs 281.42 crore. In Q1 FY27, revenue grew 4.6% to Rs 715.35 crore, and net profit rose 9.2% to Rs 132.49 crore. Operating margin was 20.21% in FY26 and 28.56% in Q1 FY27 against 27.12% a year earlier.
Debt to equity is 0.01 and return on equity is 11.32%. FY26 operating cash flow was Rs 200.45 crore against capital expenditure of Rs 186.56 crore. FDC paid a dividend of Rs 5 per share for FY26, a yield of 1.54%. At a P/E of 18.05 against an industry P/E of 37.59, the stock trades below its industry multiple.
What to watch: Q1 FY27 operating margin was 28.56% against 20.21% for FY26, so margin stability is the figure to follow as volumes grow.
Indegene: Life Sciences Outsourcing Anchors the Roadmap
Indegene’s roadmap rests on commercial, medical and regulatory services for life sciences and pharma companies, with outsourcing by drug makers supporting revenue.
Revenue grew from Rs 1,690.50 crore in FY22 to Rs 3,582.50 crore in FY26, a 111.9% rise, and FY26 revenue was 21.6% higher than FY25. FY26 net profit was Rs 401.10 crore. In Q1 FY27, revenue grew 39.5% to Rs 1,092.10 crore. Operating margin was 19.11% in FY26.
Debt to equity is 0.05 and return on equity is 12.78%. FY26 operating cash flow was Rs 650.80 crore against capital expenditure of Rs 44.30 crore. Indegene paid a dividend of Rs 2.25 per share for FY26, a yield of 0.38%. At a P/E of 35.20 against an industry P/E of 62.79, the stock trades below its industry multiple.
What to watch: The P/E of 35.20 against an industry P/E of 62.79 leaves valuation less stretched, so the next quarters’ growth is the figure to follow.
Best Contract Manufacturing, Hydration Formulation and Life Science Service Stocks in India: Akums vs FDC vs Indegene on Key Financials
Among the best contract manufacturing, hydration formulation and life science service stocks in India, Akums ranks second on FY26 revenue growth and Q1 FY27 revenue growth; FDC leads on FY26 operating margin and the lowest P/E; Indegene leads on FY26 revenue growth and Q1 FY27 revenue growth. The table puts the numbers side by side.
| Metric | Akums | FDC | Indegene |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 4,487.74 | 2,284.45 | 3,582.50 |
| FY26 revenue growth | 7.6% | 3.9% | 21.6% |
| FY26 net profit (Rs Cr) | 256.40 | 281.42 | 401.10 |
| FY26 operating profit margin | 14.47% | 20.21% | 19.11% |
| Q1 FY27 revenue growth (YoY) | 13.9% | 4.6% | 39.5% |
| Return on equity | 7.70% | 11.32% | 12.78% |
| P/E ratio | 42.26 | 18.05 | 35.20 |
| Debt to equity | 0.05 | 0.01 | 0.05 |
| Dividend yield | 0.37% | 1.54% | 0.38% |
| FY26 operating cash flow (Rs Cr) | 1,181.20 | 200.45 | 650.80 |
Healthcare earnings follow contract orders, prescription growth and client wins, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Contract Manufacturing, Hydration Formulation and Life Science Service Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen contract manufacturing, hydration formulation and life science service stocks and shortlist contract manufacturing, hydration formulation and life science service stocks to buy.
- Compare each stock’s P/E with its industry P/E, which differs by company here.
- Check revenue growth, operating margin and return on equity together.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Risks to Consider Before Investing in Contract Manufacturing, Hydration Formulation and Life Science Service Stocks
- Pricing rules: Price controls can affect margins.
- Competition: Rival brands and providers can pressure growth.
- Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.
Download the Univest iOS App or Univest Android App to track Akums, FDC and Indegene live.
Final Take: Which Stock Has the Strongest Roadmap?
These three healthcare stocks cover contract manufacturing, branded formulations and life science services. Akums ranks second on FY26 revenue growth and Q1 FY27 revenue growth; FDC leads on FY26 operating margin and the lowest P/E; Indegene leads on FY26 revenue growth and Q1 FY27 revenue growth.
Across contract manufacturing, hydration formulation and life science service stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the contract manufacturing, hydration formulation and life science service stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Contract Manufacturing, Hydration Formulation and Life Science Service Stocks
Which are the best contract manufacturing, hydration formulation and life science service stocks in India with a strong roadmap?
Ans. Akums Drugs and Pharmaceuticals, FDC and Indegene stand out for their roadmaps in contract manufacturing, branded formulations and life science services. FY26 revenue growth was 7.6% at Akums, 3.9% at FDC and 21.6% at Indegene, and return on equity ranges from 7.70% to 12.78%.
Is Akums Drugs and Pharmaceuticals a good stock to buy now?
Ans. Akums Drugs and Pharmaceuticals has a debt to equity ratio of 0.05, a return on equity of 7.70% and a P/E of 42.26 against an industry P/E of 37.59. Valuation, growth and pricing rules move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of Akums, FDC and Indegene?
Ans. The P/E ratio is 42.26 for Akums (industry 37.59), 18.05 for FDC (industry 37.59) and 35.20 for Indegene (industry 62.79). Only Akums trades at or above the industry multiple.
Which of these contract manufacturing, hydration formulation and life science service stocks has the highest return on equity?
Ans. Indegene has the highest return on equity at 12.78%, followed by FDC at 11.32% and Akums Drugs and Pharmaceuticals at 7.70%.
What are the risks of investing in contract manufacturing, hydration formulation and life science service stocks?
Ans. The main risks are pricing rules, competition and quarterly trends. Price controls can affect margins.
How did Akums, FDC and Indegene perform in Q1 FY27?
Ans. Akums Drugs and Pharmaceuticals reported revenue of Rs 1,197.01 crore, up 13.9% year on year, and net profit rose 56.1% to Rs 100.98 crore. FDC reported revenue of Rs 715.35 crore, up 4.6% year on year, and net profit rose 9.2% to Rs 132.49 crore. Indegene reported revenue of Rs 1,092.10 crore, up 39.5% year on year.
Do contract manufacturing, hydration formulation and life science service stocks pay dividends?
Ans. Yes, all three companies pay dividends. The dividend yield is 0.37% for Akums, 1.54% for FDC and 0.38% for Indegene, based on dividends declared for FY26.
How can I invest in contract manufacturing, hydration formulation and life science service stocks in India?
Ans. You can buy contract manufacturing, hydration formulation and life science service stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.
